We read with great interest the manuscript by Marot and colleagues [1]. The authors carried out a meta-analysis of randomised controlled trials (RCTs) evaluating the usefulness of granulocyte colony-stimulating factor (G-CSF, n = 197) in patients suffering from alcoholic hepatitis (AH) as compared with controls receiving placebo or pentoxifylline (n = 199). The primary and secondary endpoints aimed at assessing the risk of death at 90 days and the risk of infection, respectively. Seven RCTs, including 336 patients with AH and 60 patients with acute-on-chronic liver failure (ACLF) were analysed. Their crude conclusion is that the use of G-CSF cannot currently be recommended for patients with AH (owing to the high heterogeneity observed between the five Asian and the two European studies), although the risk of 90-day mortality (OR = 0.28; 95% CI 0.09-0.88; p = 0.03; I~2 = 80%) and the risk of infections (OR = 0.21; 95% CI 0.08-0.55; p = 0.001; I~2 = 73%) were significand reduced.
展开▼
